Elevation Oncology Plans To Expand Its Ongoing Phase 1 Trial To Include Two Combination Cohorts Evaluating EO-3021 For Advanced Gastric Or Gastroesophageal Junction Cancer. The Company Expects To Initiate Dosing In Combination Portion By Year-end 2024

6/27/24 7:32:22 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ELEV alert in real time by email

Following recently signed clinical supply agreements with Eli Lilly and Company (Lilly) and GSK, respectively, Elevation Oncology will evaluate EO-3021 in combination with ramucirumab, a VEGFR2 inhibitor, in second-line patients and in combination with dostarlimab, a PD-1 inhibitor, in the front-line setting

Get the next $ELEV alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ELEV

Date	Price Target	Rating	Analyst
5/31/2024	$10.00	Overweight	Piper Sandler
5/14/2024	$8.00	Overweight	Stephens
3/1/2024	$7.00	Mkt Outperform	JMP Securities
5/30/2023	$5.00 → $8.00	Market Perform → Outperform	SVB Securities
3/4/2022	$27.00 → $21.00	Outperform	Wedbush
12/23/2021	$12.00	Buy	HC Wainwright & Co.
7/20/2021	$24.00	Overweight	JP Morgan
7/20/2021	$27.00	Outperform	Wedbush

More analyst ratings

$ELEV
Press Releases

Fastest customizable press release news feed in the world

Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements
-- Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Progressed into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Expect to present preclinical data on the combination potential of EO-3021 with VEGFR2 or PD-1 inhibitors at ESMO Immuno-Oncology Annual Congress 2024 (ESMO-IO 2024) -- -- Expect to initiate dosing in combination portion of the Phase 1 trial of EO-3021 in 4Q 2024 -- -- On-track to nominate development candidate for HER3-ADC program in 4Q 2024 -- BOSTON, Nov. 6, 2024 /PRNewswire/ -
11/6/24 7:30:00 AM ET
$ELEV
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2
BOSTON, Sept. 23, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to EO-3021, a differentiated antibody drug conjugate (ADC), for the treatment of patients with advanced or metastatic gastric and gastroesophageal junction (GC/GEJ) cancer expressing Claudin 18.2 that has progressed on or after prior therapy. "We are delighted to receive Fast Track designation for EO-3021, which marks an enc
9/23/24 7:30:00 AM ET
$ELEV
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BOSTON, Sept. 3, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra, Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 11:30 am ET. A live webcast and replay of the event will be available on the Events page of the Company's Investor Relations website at https://investors.elevationoncology.com. About Elevation Oncology, Inc. Eleva
9/3/24 7:30:00 AM ET
$ELEV
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$ELEV
Financials

Live finance-specific insights

Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements
-- Today announced promising initial data from Phase 1 clinical trial of EO-3021; 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Secured clinical supply agreements to evaluate EO-3021 in combination with ramucirumab and dostarlimab with Lilly and GSK, respectively; expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 -- -- On-track to nominate development candidate for HER3-ADC program in 2H 2024 -- -- Elevation Oncology to host conference call and webcast today at 8:30
8/6/24 7:10:00 AM ET
$ELEV
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2
-- 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer ---- EO-3021 demonstrated differentiated safety profile, with minimal MMAE-associated toxicities, including no neutropenia or peripheral neuropathy/hypoesthesia -- -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 ---- Expect to initiate dosing in combination portion of Phase 1 trial by year-end 2024 ---- Elevation Oncology to host conference call and webcast today at 8:30 a.m. ET -- BOSTON, Aug. 6, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective ca
8/6/24 7:00:00 AM ET
$ELEV
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group
Obtains exclusive worldwide rights (outside Greater China) to develop and commercialize EO-3021 (SYSA1801)Expands pipeline to now include two clinical stage precision oncology candidates for patients with genomically defined solid tumors, including those with Claudin18.2 overexpressionCompany expects to initiate a Phase 1 clinical trial in the U.S. evaluating EO-3021 (SYSA1801) in 2023Management to host an investor conference call and webcast today at 5:00 p.m. ET NEW YORK, July 28, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), a clinical stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, tod
7/28/22 8:45:00 AM ET
$ELEV
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors
BOSTON, March 4, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointments of Julie Cherrington, Ph.D. and Alan Sandler, M.D., to its Board of Directors. "We are thrilled to welcome Julie and Alan as Elevation Oncology's newest directors," said Steve Elms, Chairman of Elevation Oncology. "Both are extremely experienced drug developers, who have contributed to the advancement and approval of multiple targeted therapies for the treatment of cancer. On behalf of the Board,
3/4/24 7:30:00 AM ET
$ELEV
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors
BOSTON, Jan. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointment of Darcy Mootz, Ph.D., to its Board of Directors. Dr. Mootz is an experienced life sciences executive, who brings expertise across corporate strategy, corporate development, finance, and operations to Elevation Oncology's Board of Directors. "We are pleased to welcome Darcy to the Elevation Oncology board, as she is a uniquely qualified leader, who has experience crafting late-stage development str
1/22/24 7:30:00 AM ET
$ELEV
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer
NEW YORK, July 13, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, announced today the appointment of Joseph Ferra, M.B.A., as its Chief Executive Officer. Mr. Ferra was previously Interim Chief Executive Officer and Chief Financial Officer. Mr. Ferra will also join the Elevation Oncology Board of Directors. In addition, the Company announced the appointment of Tammy Furlong, M.B.A., C.P.A., as Chief Financial Officer, promoted from her previous role as Vice President of Finance and Accounting
7/13/23 8:00:00 AM ET
$ELEV
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Elevation Oncology Plans To Expand Its Ongoing Phase 1 Trial To Include Two Combination Cohorts Evaluating EO-3021 For Advanced Gastric Or Gastroesophageal Junction Cancer. The Company Expects To Initiate Dosing In Combination Portion By Year-end 2024

Chat with this insight

Recent Analyst Ratings for $ELEV

$ELEV SEC Filings

Elevation Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Elevation Oncology Inc.

Elevation Oncology Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

$ELEV Press Releases

Fastest customizable press release news feed in the world

Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements

Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2

Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

$ELEV Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Piper Sandler initiated coverage on Elevation Oncology with a new price target

Stephens initiated coverage on Elevation Oncology with a new price target

JMP Securities initiated coverage on Elevation Oncology with a new price target

$ELEV Financials

Live finance-specific insights

Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements

Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2

Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group

$ELEV Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CHIEF FINANCIAL OFFICER Furlong Tammy converted options into 300 shares and covered exercise/tax liability with 98 shares, increasing direct ownership by 17% to 1,410 units (SEC Form 4)

CHIEF EXECUTIVE OFFICER Ferra Joseph J Jr converted options into 12,562 shares and covered exercise/tax liability with 4,628 shares, increasing direct ownership by 8% to 101,548 units (SEC Form 4)

CHIEF FINANCIAL OFFICER Furlong Tammy converted options into 300 shares and covered exercise/tax liability with 89 shares, increasing direct ownership by 21% to 1,208 units (SEC Form 4)

$ELEV Market Insights

Live Market Insights

GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing

JMP Securities Reiterates Market Outperform on Elevation Oncology, Maintains $7 Price Target

JMP Securities Reiterates Market Outperform on Elevation Oncology, Maintains $7 Price Target

$ELEV Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

$ELEV Leadership Updates

Live Leadership Updates

Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors

Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors

Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer

Recent Analyst Ratings for
$ELEV

$ELEV
SEC Filings

$ELEV
Press Releases

$ELEV
Analyst Ratings

$ELEV
Financials

$ELEV
Insider Trading

$ELEV
Market Insights

$ELEV
Large Ownership Changes

$ELEV
Leadership Updates